ITOS Key Statistics, Chart & Performance
The current stock price of ITOS is 10.15 USD. In the past month the price increased by 0.1%. In the past year, price decreased by -39.76%.
ITOS Latest News, Press Relases and Analysis
ITOS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.09 | 402.18B | ||
| AMGN | AMGEN INC | 15.76 | 185.50B | ||
| GILD | GILEAD SCIENCES INC | 15.57 | 158.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.89 | 110.80B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.43 | 83.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 872.78 | 58.35B | ||
| INSM | INSMED INC | N/A | 43.23B | ||
| NTRA | NATERA INC | N/A | 32.54B | ||
| BIIB | BIOGEN INC | 10.87 | 26.67B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.51 | 22.09B | ||
| INCY | INCYTE CORP | 16.46 | 20.63B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.21B |
Related stock screener links
About ITOS
Company Profile
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. The company is headquartered in Watertown, Massachusetts and currently employs 173 full-time employees. The company went IPO on 2020-07-24. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its EOS-984, a potentially first-in-class small molecule, focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1, a dominant transporter of extracellular adenosine, expressed on intratumoral T cells, which allows adenosine entry into the cell, disturbing T cell metabolism, expansion, effector function, and survival. The company is also developing EOS-215, a potential best-in-class monoclonal antibody which antagonizes the triggering receptor expressed on myeloid cells 2.
Company Info
ITEOS THERAPEUTICS INC
321 Arsenal Street, Bldg 312, Floor 3, Suite 301
Watertown MASSACHUSETTS 02142 US
CEO: Michel Detheux
Employees: 173
Phone: 18572044583
ITEOS THERAPEUTICS INC / ITOS FAQ
What does ITOS do?
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. The company is headquartered in Watertown, Massachusetts and currently employs 173 full-time employees. The company went IPO on 2020-07-24. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its EOS-984, a potentially first-in-class small molecule, focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1, a dominant transporter of extracellular adenosine, expressed on intratumoral T cells, which allows adenosine entry into the cell, disturbing T cell metabolism, expansion, effector function, and survival. The company is also developing EOS-215, a potential best-in-class monoclonal antibody which antagonizes the triggering receptor expressed on myeloid cells 2.
What is the stock price of ITEOS THERAPEUTICS INC today?
The current stock price of ITOS is 10.15 USD. The price increased by 0.2% in the last trading session.
Does ITOS stock pay dividends?
ITOS does not pay a dividend.
What is the ChartMill technical and fundamental rating of ITOS stock?
ITOS has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists ITOS stock?
ITOS stock is listed on the Nasdaq exchange.
Can you provide the number of employees for ITEOS THERAPEUTICS INC?
ITEOS THERAPEUTICS INC (ITOS) currently has 173 employees.
ITOS Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ITOS. When comparing the yearly performance of all stocks, ITOS is a bad performer in the overall market: 89.45% of all stocks are doing better.
ITOS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ITOS. While ITOS has a great health rating, there are worries on its profitability.
ITOS Financial Highlights
Over the last trailing twelve months ITOS reported a non-GAAP Earnings per Share(EPS) of -4.31. The EPS decreased by -43.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.57% | ||
| ROE | -27.22% | ||
| Debt/Equity | 0 |
ITOS Forecast & Estimates
10 analysts have analysed ITOS and the average price target is 10.56 USD. This implies a price increase of 4% is expected in the next year compared to the current price of 10.15.
For the next year, analysts expect an EPS growth of -7.51% and a revenue growth -100% for ITOS